Clinical trials: Remission of Ulcerative Colitis
Ulcerative Colitis, Colorectal Cancer
Objective Perfusion Rate Assessment by Near-infrared Fluorescence in Ileal Pouch Formation and Ileal-pouch-anal Anastomosis
In this prospective, non-randomized cohort study, real-time intraoperative visualization using near-infrared-fluorescence by indocyanine green injection (ICG-NIRF) is performed at three time points during ileal pouch…
- Conditions
- Ulcerative Colitis, Colorectal Cancer, Crohn Disease, Familial Adenomatous Polyposis
- Trial name
- NCT04695964
- Testing
- ICG-NIRF Imaging plus ingress and egress analysis
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Charite University, Berlin, Germany
Ulcerative Colitis
Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
Ulcerative colitis is a disease of the large bowel (colon) and rectum in which the lining of the bowel becomes red and swollen. Over time, patients with this disease may experience acute episodes of diarrhea, rectal bleeding and…
- Trial name
- NCT00151892
- Testing
- SPD476, Asacol
- Where
- 142 sites in United States, Argentina and 26 more
- Volunteers
- 829 people
- Sponsor
- Shire
Ulcerative Colitis
Fecal Biotherapy for the Induction of Remission in Active Ulcerative Colitis
Ulcerative colitis is a condition that mainly affects young adults where the lining of the bowel is inflamed causing bloody diarrhea.
- Trial name
- NCT01545908
- Testing
- Fecal transplant
- Where
- 2 sites in Canada
- Volunteers
- 130 people
- Sponsor
- Hamilton Health Sciences Corporation
Ulcerative Colitis, Inflammatory Bowel Diseases
Open Label Study to Assess Safety & Efficacy of QD for Induction of Remission in Pediatric Patients with UC
To date, there are no reports on the use of QD in pediatric patients with UC. There is a great need to increase the repertoire of anti-inflammatory interventions for remission induction, especially in children given the notorious…
- Trial name
- NCT06777706
- Testing
- QD (Qing Dai)
- Where
- 2 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Shaare Zedek Medical Center
Ulcerative Colitis
A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission
Participants who were in clinical remission on 200 milligram (mg) filgotinib once daily for at least 2 consecutive quarterly visits in the ongoing SELECTION-LTE study (GS-US-418-3899, NCT02914535), were planned to be rolled over…
- Trial name
- CAPYBARA (NCT05479058)
- Testing
- Filgotinib
- Where
- 50 sites in United States, Belgium and 11 more
- Volunteers
- 22 people
- Sponsor
- Lakefront Biotherapeutics NV
Ulcerative Colitis, Flare Up, Symptom
Effectiveness of Golimumab in Patients With Ulcerative Colitis: Results of a Real-life Study in Switzerland
TNF inhibitors have improved treatment options for patients with inflammatory bowel disease (IBD) and three TNF inhibitors, infliximab, adalimumab and golimumab are available for treatment of ulcerative colitis in Switzerland.
- Trial name
- NCT05405465
- Testing
- Exposure to golimumab
- Where
- Switzerland
- Volunteers
- 103 people
- Sponsor
- University of Zurich
Ulcerative Colitis
Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis
The investigators will test the hypothesis that giving antibiotics prior to fecal transplant therapy for active UC increases the proportion of patients in remission at the end of treatment.
- Trial name
- FMT (NCT02606032)
- Testing
- Metronidazole, Doxycycline, Terbinafine
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- Hamilton Health Sciences Corporation
Ulcerative Colitis
TOFACITINIB vs TOFACITINIB WITH MESALAMINE IN ULCERATIVE COLITIS
All the trials using tofacitinib for maintenance of remission in UC have allowed the use of concomitant therapies except glucocorticoids.
- Trial name
- NCT06625450
- Testing
- Tofacitinib, Tofacitinib plus mesalamine
- Volunteers
- 75 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Pediatric Ulcerative Colitis in Remission
Oral Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis
The purpose of this study is to evaluate whether FMT by frozen stool capsules in pediatric UC patients in remission after corticosteroid treatment, can modify their dysbiotic gut microbiota by increasing the richness of their…
- Trial name
- T-FORE (NCT05202990)
- Testing
- Fecal Microbiota Transplantation by Stool capsules, Fecal Microbiota Transplantation by Intra-rectal enemas
- Where
- 3 sites in France
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ulcerative Colitis
Profermin® in Active Ulcerative Colitis
In this study the investigators aim was to investigate the safety and possible efficacy of Profermin® in patients with ulcerative colitis.
- Trial name
- CUPE-1 (NCT01245465)
- Testing
- Profermin
- Volunteers
- 39 people
- Sponsor
- Nordisk Rebalance A/S
Ulcerative Colitis in Remission
Effect of Procyanidins in Leaky Gut Repairing in IBD
The goal of this clinical trial is to learn if the Grape Seed Extract Ecovitis, featuring low monomeric catechins content and a high concentration of oligo-polymeric procyanidins, could modulate the Gut Microbiota composition of…
- Trial name
- EcoVitis (NCT06576700)
- Testing
- Grape Seed Extracts
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- University of Padova
Ulcerative Colitis
A Comparison of Once a Day Dose Compared to 2 Doses/Day
The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.
- Trial name
- NCT00505778
- Testing
- Mesalamine Once-Daily, Mesalamine Twice-Daily
- Where
- 245 sites in United States, Canada and 1 more
- Volunteers
- 1,027 people
- Sponsor
- Warner Chilcott
Ulcerative Colitis
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission designed to evaluate flexible dosing of CP-690,550.
- Trial name
- NCT03281304
- Testing
- CP-690,500 5 mg, CP-690,550 10 mg
- Where
- 80 sites in United States, Belgium and 18 more
- Volunteers
- 140 people
- Sponsor
- Pfizer
Ulcerative Colitis in Remission, Ultrasound
Predicting Relapse of Ulcerative Colitis With Gastrointestinal Ultrasound
Rationale: Ulcerative colitis (UC) is remitting disease with a variable course. Predicting disease relapse after remission is important for the adjustment of medical treatment.
- Conditions
- Ulcerative Colitis in Remission, Ultrasound, Relapse/Recurrence
- Trial name
- PRELAPSE (NCT03501758)
- Testing
- Ultrasound, Analysis of prouroguanyline and uroguanyline in full blood
- Where
- 2 sites in Norway
- Volunteers
- 40 people
- Sponsor
- Haukeland University Hospital
Crohn Disease, Ulcerative Colitis
Digital Nutrition Therapy for Patients With IBD
Background: Alberta's Center of Excellence for Nutrition in Digestive Diseases (Ascend) is dedicated to generating new discoveries regarding the link between nutrition and digestive diseases and mobilizing existing research to…
- Trial name
- LYFEMD (NCT04653259)
- Testing
- LYFE MD app
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- University of Calgary
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
Fecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UC
Ulcerative colitis is a chronic idiopathic inflammatory disease of the colon that is characterized by abdominal pain and bloody diarrhea.
- Trial name
- NCT03716388
- Testing
- Fecal Microbiota Transplantation, Mesalamine Granules
- Where
- India
- Volunteers
- 20 people
- Sponsor
- Dayanand Medical College and Hospital
Crohn's Disease, Ulcerative Colitis
Evaluation of Molecular Mechanisms of Non-response to Therapy in Patients With Inflammatory Bowel Disease
Inflammatory bowel diseases (IBD) represent a group of immune-mediated disorders, in which currently unidentified trigger factors drive the manifestation of chronic relapsing- remitting destructive inflammatory episodes in the…
- Trial name
- 3TR (NCT05733845)
- Testing
- Samples
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Colitis, Ulcerative
A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M
IBD98-M-2002 is a phase 2a , Randomized, Double blind, Placebo-controlled of IBD98-M Delayed Release capsules in subjects with Mild to Moderately Ulcerative Colitis to investigate the clinical efficacy of IBD98-M delayed release…
- Trial name
- NCT02493712
- Testing
- High dose, Low dose
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Ulcerative Colitis
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis
There are fewer therapeutic options for patients with active ulcerative colitis (UC) compared to patients with active Crohn's disease (CD) and the investigators are facing a persistent unmet need for additional effective and…
- Trial name
- Merit-UC (NCT01393405)
- Testing
- Methotrexate
- Where
- 31 sites in United States
- Volunteers
- 179 people
- Sponsor
- University of North Carolina, Chapel Hill
Ulcerative Colitis
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
This Phase III, double-blind, placebo and active-comparator controlled, multicenter study will investigate the efficacy and safety of etrolizumab in induction of remission in participants with moderately to severely active…
- Trial name
- HIBISCUS II (NCT02171429)
- Testing
- Adalimumab, Etrolizumab
- Where
- 90 sites in United States, Argentina and 17 more
- Volunteers
- 358 people
- Sponsor
- Hoffmann-La Roche